Zydus Lifesciences' New Jersey Office clears USFDA inspection with zero observations

The USFDA conducted onsite inspection of pharmacovigilance and post marketing surveillance system at the company’s office based in New Jersey, USA. The inspection was conducted from 22nd September to 25th September 2026. The inspection closed with NIL observations.

RPG Active Pharma approves merger with Actis Generics

RPG Active Pharma Limited, a wholly owned subsidiary of RPG Life Sciences Limited, has approved a scheme of amalgamation to merge its own wholly owned subsidiary, Actis Generics Private Limited, into itself. Approved by the board of directors on September 25, 2026, this corporate restructuring is designed to consolidate the group's assets, streamline overall business operations, and eliminate duplicate administrative costs.